CD47-SIRPα Checkpoint Disruption in Metastases Requires Tumor-Targeting Antibody for Molecular and Engineered Macrophage Therapies

CD47-SIRPα Checkpoint Disruption in Metastases Requires Tumor-Targeting Antibody for Molecular and Engineered Macrophage Therapies

The macrophage checkpoint interaction CD47-SIRPα is an emerging target for cancer therapy, but clinical trials of monoclonal anti-CD47 show efficacy only in liquid tumors when combined with tumor-opsonizing IgG. Here, in challenging metastatic solid tumors, CD47 deletion shows no effect on tumor gro...

Full description

Bibliographic Details
Main Authors: Jason C. Andrechak, Lawrence J. Dooling, Michael P. Tobin, William Zhang, Brandon H. Hayes, Justine Y. Lee, Xiaoling Jin, Jerome Irianto, Dennis E. Discher
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Cancers
Subjects:
macrophage checkpoint
CD47
metastasis
melanoma
cell therapy
SIRPα
Online Access:https://www.mdpi.com/2072-6694/14/8/1930

Internet

https://www.mdpi.com/2072-6694/14/8/1930

Similar Items